Factor Model (net -3.2)
Factor Model
net -3.2 5.7 / 10Guidance cut despite 12% revenue growth and debt extension
Watch: Monitor how aggressively that major carrier ramps marketing spend again in H2 2026 — without it, the company risks missing the reset guidance. Also track the PBM reimbursement impact: if the January agreement doesn't stabilize rates as promised, SLQT could face further cuts.
SelectQuote posted FQ2 2026 revenue of $537 million, up 12% year-over-year, with SelectRx surging 26% — showing core momentum in the healthcare segment. But the company slashed FY2026 guidance by $40 million due to a major carrier slashing marketing budgets and reimbursement pressures from pharmacy benefit managers. The company bought itself breathing room with a new $415 million senior credit facility extending debt maturities to 2031, though a $20 million EBITDA headwind from PBM reimbursement shifts looms for 2026. A new multi-year PBM agreement signed in January may cushion future rate volatility.
The guidance cut overshadows solid top-line growth and reveals client concentration risk — when one carrier's marketing spend drops, the entire year unravels. The refinancing buys time, but SLQT's real problem isn't liquidity; it's that revenue visibility is fragile and margin headwinds are structural, not temporary. The SelectRx growth is a bright spot, but it can't offset near-term PBM pressure.
Evidence
Fundamentals & Data ▾
Recent transactions
Get alerted when SLQT changes direction
We'll email you when our AI detects a shift — reversals, insider clusters, filing red flags.